Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY).
Mult Scler Relat Disord
; 22: 27-34, 2018 May.
Article
en En
| MEDLINE
| ID: mdl-29524759
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Esclerosis Múltiple Recurrente-Remitente
/
Dimetilfumarato
/
Natalizumab
/
Factores Inmunológicos
Tipo de estudio:
Guideline
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Adolescent
/
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Mult Scler Relat Disord
Año:
2018
Tipo del documento:
Article